摘要
近年来革兰阴性杆菌血流感染率呈持续增加趋势,其中耐药菌所致感染病死率更高、住院时间更长,尤其是耐碳青霉烯类鲍曼不动杆菌(CRAB)血流感染。多黏菌素于20世纪50年代开始用于临床,具有对多重耐药和广泛耐药革兰阴性杆菌抗菌活性,也可作为革兰阴性杆菌细胞包膜的有效通透剂。多黏菌素保留应用于微生物学明确的耐药革兰阴性杆菌感染,世界卫生组织将其分类为对人类感染具有重要临床意义的抗菌药物,可以用于治疗耐药鲍曼不动杆菌感染。本文对多黏菌素治疗耐药鲍曼不动杆菌血流感染的临床治疗进行综述,以期对临床医生用药提供参考。
In recent years,the bloodstream infection rate of Gram-negative bacilli has continued to increase.Among them,drug-resistant bacteria have a higher mortality rate and longer hospital stay,especially the bloodstream infection of carbapenem-resistant Acinetobacter baumannii(CRAB).Polymyxin began to be used clinically in the 1950s and has antibacterial activity against multidrug resistant and poly drug-resistant Gram-negative bacilli.It can also be used as an effective permeation agent for the cell envelope of Gram-negative bacilli.Polymyxin is reserved for microbiologically clear drug-resistant Gram-negative bacilli infections.The World Health Organization classifies polymyxin as an antimicrobial drug with clinical significance for human infections and can be used to treat drug-resistant Acinetobacter baumannii infection.This article reviews the clinical treatment of polymyxin in bloodstream infections of drug-resistant Acinetobacter baumannii,to provide reference for clinical medication.
作者
张曙光
孙留涛
孙利敏
杨子悦
Zhang Shuguang;Sun Liutao;Sun Limin;Yang Ziyue(Department of Critical Care Medicine/General Intensive Care Unit(2),the First Affiliated Hospital of Zhengzhou University,Zhengzhou 450018,Henan,China)
出处
《中华危重病急救医学》
CAS
CSCD
北大核心
2021年第11期1401-1404,共4页
Chinese Critical Care Medicine
基金
河南省卫生健康科技英才海外研修工程项目(HWYX2019020)。
关键词
多黏菌素
耐碳青霉烯类鲍曼不动杆菌
血流感染
多重耐药
泛耐药
Polymyxin
Carbapenem-resistant Acinetobacter baumannii
Bloodstream infection
Multidrug resistant
Extensively drug resistant
